findmyKOL
Clinical trialNCT06487039RecruitingPhase 2Interventional

Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration

SponsorEyebioKorea, Inc.Enrollment50Neovascular Age-related Macular Degeneration (nAMD)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Trial to Evaluate the Safety and Efficacy of EB-203 in Patients with Neovascular Age-related Macular Degeneration. The purpose of this study is to primarily investigate the safety and tolerability of EB-203 by dose in patients with neovascular Age-related Macular Degeneration (nAMD), and to secondarily evaluate the clinical efficacy. Subject to Adults aged 50 years or older and Neovascular age-related macular degeneration (nAMD)
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

South Korea
  • Busan Paik Hospital, Inje University

    Busan, South Korea

    Recruiting
  • Pusan National University Hospital

    Busan, South Korea

    Recruiting
  • Yeungnam University Medical Center

    Daegu, South Korea

    Recruiting
  • Kim'S Eye Hospital

    Seoul, South Korea

    Recruiting
  • Seoul National University Hospital

    Seoul, South Korea

    KyuHyeong PARK
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

EB-203
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Aug 2024
Primary completion
31 Aug 2025
Completion
31 Jan 2026
Last update posted
27 Aug 2024
Registered enrollment
50
Registry id
NCT06487039
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.